Skip to content

Contrast-enhanced Multispectral Optoacoustic Tomography for Non-invasive Assessment of Diabetic Gastroparesis

Contrast-enhanced Multispectral Optoacoustic Tomography for Non-invasive Assessment of Diabetic Gastroparesis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05935852
Acronym
TRANSPARENT
Enrollment
40
Registered
2023-07-07
Start date
2023-07-15
Completion date
2023-12-24
Last updated
2023-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Gastroparesis

Keywords

diabetic gastroparesis, MSOT

Brief summary

The objective of the proposed study is to assess gastric emptying time (GET) based on contrast-enhanced multispectral optoacoustic imaging (CE-MSOT) in a collective of patients with type 1 diabetes mellitus (T1DM). The results will be correlated with disease duration and severity.

Detailed description

T1DM is a chronic autoimmune disease in which autoantibodies destroy the pancreas's insulin-producing cells. In Germany, it is estimated that 32,000 children and adolescents and approximately 335,000 adults suffer from T1DM. The trend has been increasing in recent years. A complication of T1DM is diabetic gastroparesis (DGP), in which gastric emptying is delayed without mechanical obstruction. Symptoms of DGP include nausea, vomiting, and abdominal pain. Many patients\* are asymptomatic. DGP is associated with higher HbA1c, autonomic neuropathy, nephropathy, retinopathy, and increased gastrointestinal symptoms. In this study, gastric emptying will be imaged noninvasively and without radiation based on MSOT. MSOT, in addition to imaging endogenous chromophores, allows visualization of exogenous chromophores. If the dye indocyanine green (ICG) is ingested orally, the signal of the dye in the lumen of the gastrointestinal tract can be visualized noninvasively by MSOT over different intestinal segments. If food is labeled with ICG and ingested by subjects\*, the passage of chyme through the gastrointestinal tract can be tracked by measuring the signal with MSOT, and transit times can be measured. This study will investigate gastric emptying times of patients\* with T1DM.

Interventions

Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Four Arms with different disease activity and duration

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

nclusion criteria Group 1 * Written informed consent * T1DM diagnosis * Duration of disease at least 5, preferably 10 years with diagnosed neuropathy Group 2 * Written informed consent * T1DM diagnosis * Duration of disease at least 5, preferably 10 years without diagnosed neuropathy Group 3 * Written informed consent from parent or guardian * T1DM diagnosis * Duration of disease at least 5, preferably 10 years with inadequate medication control (HbA1c value \> 8.5 mmol/l) Group 4 * Written informed consent of parent or guardian * T1DM diagnosis * Duration of disease at least 5, preferably 10 years with good medication control (HbA1c value \< 7.5 mmol/l)

Exclusion criteria

Generality: * Pregnancy * Breastfeeding mothers * Tattoo in the area of the examination * Subcutaneous fat tissue over 3 cm * Known hypersensitivity to ICG, sodium iodide or iodine * Hyperthyroidism, focal or diffuse thyroid autonomy * Timely close treatment to check thyroid function with ingestion of radioactive iodine (within two weeks before or after the study) * Impaired renal function * Taking the following medications: Beta blockers, anticonvulsants, cyclopropane, bisulfite compounds, haloperidol, heroin, meperidine, metamizole, methadone, morphine, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, probenecid, rifamycin, any injection containing sodium bisulfite

Design outcomes

Primary

MeasureTime frameDescription
Gastric emptying time6 hoursGastric emptying time based on MSOT imaging of ICG-signal intensity

Secondary

MeasureTime frameDescription
Correlation of acquired hemoglobin signal with disease activity6 hoursHemoglobin-associated parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with disease activity
Correlation of acquired hemoglobin signal with disease duration6 hoursHemoglobin-associated parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with disease duration

Contacts

Primary ContactFerdinand Knieling
ferdinand.knieling@uk-erlangen.de+4991318541151
Backup ContactEmmanuel Nedoschill
emmanuel.nedoschill@uk-erlangen.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026